Pharmacopsychiatry

2.7(top 20%)

impact factor

4.6K(top 5%)

papers

69.7K(top 5%)

citations

98(top 5%)

h-index

2.8(top 20%)

impact factor

5.4K

all documents

72.0K

doc citations

150(top 5%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017	Pharmacopsychiatry	2018	787
2	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011	Pharmacopsychiatry	2011	774
3	The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry	Pharmacopsychiatry	2004	453
4	Course of the Manic-Depressive Cycle and Changes Caused by Treatments	Pharmacopsychiatry	1980	391
5	Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761 in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-infarct Dementia	Pharmacopsychiatry	1996	381
6	The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans	Pharmacopsychiatry	1998	376
7	Biologically Active and Other Chemical Constituents of the Herb ofHypericum perforatumL.	Pharmacopsychiatry	1997	366
8	The Revised Monoamine Theory of Depression: A Modulatory Role for Monoamines, Based on New Findings From Monoamine Depletion Experiments in Humans	Pharmacopsychiatry	1996	344
9	Adaptation of N-Methyl-D-Aspartate (NMDA) Receptors following Antidepressant Treatment: Implications for the Pharmacotherapy of Depression	Pharmacopsychiatry	1996	320
10	St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical Efficacy	Pharmacopsychiatry	1998	317
11	Serotonin Receptors and Animal Models of Aggressive Behavior	Pharmacopsychiatry	1995	280
12	Effects of Hypericum Extract (LI 160) in Biochemical Models of Antidepressant Activity	Pharmacopsychiatry	1997	277
13	Hyperforin Represents the Neurotransmitter Reuptake Inhibiting Constituent of Hypericum Extract	Pharmacopsychiatry	1998	273
14	Obesity and Related Metabolic Abnormalities during Antipsychotic Drug Administration: Mechanisms, Management and Research Perspectives	Pharmacopsychiatry	2002	244
15	Correlations and Discrepancies between Serum and Brain Tissue Levels of Neurotrophins after Electroconvulsive Treatment in Rats	Pharmacopsychiatry	2009	243
16	Epidemiological Evidence for a Low Abuse Potential of Zolpidem	Pharmacopsychiatry	2000	239
17	The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry	Pharmacopsychiatry	2005	236
18	Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary Report	Pharmacopsychiatry	2008	235
19	Effect of Prophylactic Treatment on Suicide Risk in Patients with Major Affective Disorders	Pharmacopsychiatry	1996	231
20	Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate	Pharmacopsychiatry	2009	231
21	Circadian Rhythm Mechanisms in Affective Illness and in Antidepressant Drug Action	Pharmacopsychiatry	1982	228
22	Non-Medical Use of Prescription Stimulants and Illicit Use of Stimulants for Cognitive Enhancement in Pupils and Students in Germany	Pharmacopsychiatry	2011	226
23	The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus Lorazepam	Pharmacopsychiatry	1985	219
24	Kava-kava Extract WS 1490 versus Placebo in Anxiety Disorders - A Randomized Placebo-controlled 25-week Outpatient Trial	Pharmacopsychiatry	1997	218
25	Dynamics of Neuronal Circuits in Addiction: Reward, Antireward, and Emotional Memory	Pharmacopsychiatry	2009	218
26	The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls	Pharmacopsychiatry	1998	212
27	Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial	Pharmacopsychiatry	2002	210
28	Critical Evaluation of the Effect of Valerian Extract on Sleep Structure and Sleep Quality	Pharmacopsychiatry	2000	209
29	Antidepressant Activity of Hypericum Perforatum and Hyperforin: the Neglected Possibility	Pharmacopsychiatry	1998	204
30	Oxcarbazepine in Affective and Schizoaffective Disorders	Pharmacopsychiatry	2001	203
31	Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers	Pharmacopsychiatry	1998	202
32	Effects of the Total Extract and Fractions ofHypericum perforatumin Animal Assays for Antidepressant Activity	Pharmacopsychiatry	1997	195
33	Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans	Pharmacopsychiatry	1997	184
34	Results of a Phase II Study of the Antidepressant Effect of Rolipram	Pharmacopsychiatry	1984	176
35	Controlled Clinical Trials of Hypericum Extracts in Depressed Patients - an Overview	Pharmacopsychiatry	1997	174
36	Imbalance between Pro- and Anti-inflammatory Cytokines, and between Th1 and Th2 Cytokines in Depressed Patients: The Effect of Electroacupuncture or Fluoxetine Treatment	Pharmacopsychiatry	2009	173
37	Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers	Pharmacopsychiatry	2005	172
38	The Use of Tiagabine in Affective Disorders	Pharmacopsychiatry	2002	171
39	Delineating the Longitudinal Structure of Depressive Illness: Beyond Clinical Subtypes and Duration Thresholds	Pharmacopsychiatry	2000	169
40	The Role of Corticotropin-Releasing Factor in the Pathogenesis of Major Depression	Pharmacopsychiatry	1988	168
41	Reflections on the Topics: EEG Frequency Bands and Regulation of Vigilance	Pharmacopsychiatry	1979	167
42	Fluoxetine in Alzheimer's Disease with Severe Obsessive Compulsive Symptoms and a Low Density of Serotonin Transporter Sites	Pharmacopsychiatry	2003	164
43	Atypical Antipsychotics and New Onset Diabetes mellitus	Pharmacopsychiatry	2004	164
44	Successful Treatment of Chronic Resistant Alcoholism by Deep Brain Stimulation of Nucleus Accumbens: First Experience with Three Cases	Pharmacopsychiatry	2009	162
45	REM Sleep Instability – A New Pathway for Insomnia?	Pharmacopsychiatry	2012	161
46	Does Lithium Exert an Independent Antisuicidal Effect?	Pharmacopsychiatry	2001	156
47	Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine	Pharmacopsychiatry	2003	154
48	Critical Flicker Fusion Frequency (CFF): The Effects of Psychotropic Compounds	Pharmacopsychiatry	1982	152
49	In VitroReceptor Binding and Enzyme Inhibition byHypericum perforatumExtract	Pharmacopsychiatry	1997	150
50	Can a Rapidly-eliminated Hypnotic Cause Daytime Anxiety?	Pharmacopsychiatry	1989	149

Scientometrics

Overviews

Citing Bodies

Pharmacopsychiatry

Top Articles